

## BASIC RESEARCH

# Chemical composition of the essential oil from *Kelussia odoratissima* Mozaff. and the evaluation of its sedative and anxiolytic effects in mice

Mohammed Rabbani,<sup>I</sup> Seyed Ebrahim Sajjadi,<sup>II</sup> Masoud Sadeghi<sup>III</sup>

<sup>I</sup>Department of Pharmacology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran. <sup>II</sup>Department of Pharmacognosy, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran. <sup>III</sup>Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.

**OBJECTIVE:** The present study aimed to evaluate the sedative and anxiolytic effects of the essential oils and hydroalcoholic extract of *Kelussia odoratissima* Mozaff. (*K. odoratissima*) in mice by utilizing an elevated plus maze. The chemical composition of its essential oil was also determined.

**METHODS:** The hydroalcoholic extract or essential oil fraction from this plant were administered intraperitoneally to male mice at various doses 30 min before testing. The anxiolytic and sedative effects were determined by an elevated plus maze and locomotor activity tests, respectively.

**RESULTS:** According to the results, none of the administered doses of hydroalcoholic extract or essential oil fraction of *K. odoratissima* changed the percentage of the time spent or number of entries into the open arms of the elevated plus maze. In contrast, the cumulative spontaneous locomotor activity of mice treated with the essential oil or hydroalcoholic extract was significantly decreased. Chemical analysis of the essential oil by Gas chromatography-mass spectrometry (GC-MS) showed that 3-butylidene-4,5-dihydrophthalide (85.9%) was the major component.

**CONCLUSION:** These data confirm the sedative properties of *K. odoratissima*, yet there were no profound anxiolytic effects observed.

**KEYWORDS:** Anti-anxiety; Sedative; *Kelussia odoratissima*; Elevated plus maze; Locomotor activity.

Rabbani M, Sajjadi SE, Sadeghi M. Chemical composition of the essential oil from *Kelussia odoratissima* Mozaff. and the evaluation of its sedative and anxiolytic effects in mice. Clinics. 2011;66(5):843-848.

Received for publication on November 7, 2010; First review completed on December 2, 2010; Accepted for publication on January 27, 2011

E-mail: rabanim@yahoo.com

Tel.: 98 311 7922646

## INTRODUCTION

Anxiety disorders are among the most varied mental disorders, and they normally have a considerable impact on quality of life. Substantial and prolonged stress and anxiety can adversely affect immune function, hormone levels, enzymes and gastrointestinal function. With a worldwide occurrence of 16.6%, anxiety disorders are among the most common mental disorders and a major cause of disability.<sup>1</sup> A wide range of medications are available for the treatment of stress and anxiety-related conditions; however, none of these therapies are completely safe and without adverse effects. Interventions for stress and anxiety range from nutritional support to the use of medications such as benzodiazepines, antidepressants,  $\beta$ -blockers and antipsychotics.<sup>2</sup>

In the search for safer therapeutic products, researchers worldwide have explored traditional remedies to find a suitable treatment for anxiety-related disorders.<sup>3-7</sup> Among the tested herbal extracts, kava has been shown to produce some of the best results in relieving anxiety symptoms,<sup>2</sup> although its association with hepatotoxicity is of a significant concern. Recently, a United States Patent (No. 6,582,735) was granted for the use of an extract from *Magnolia officinalis* bark for stress-related conditions involving elevated cortisol, which may include patients presenting with poor control of body weight, sleep disturbances and restlessness. In Iran, a favorable climate and geography have contributed to a diversity of medicinal plants, and many endemic plant species exist. The Umbelliferae family contains approximately 275 genera and 2,850 species.<sup>8</sup> *Kelussia* is one of the newest genera of this family and is represented by only one species, *Kelussia odoratissima* Mozaff., which is found only in Iran.<sup>9</sup> This sweet-smelling, self-growing monotypic medicinal plant is endemic to a restricted area in western Iran and locally called "Karafs-ekoohi". The aerial part of the plant is commonly used as a popular garnish and a sedative medicinal plant. Currently,

**Copyright** © 2011 CLINICS – This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

there are limited studies examining the pharmacological properties of this plant. Except for a recent publication on the antioxidant activity of *K. odoratissima*,<sup>10</sup> there have been no other published reports regarding the pharmacology of this plant.

As a continuation of our previous studies on sedative medicinal plants growing wild in Iran, this study aimed to examine the anxiolytic and sedative effects of *K. odoratissima*. The major constituents of the essential oils derived from this plant were also investigated by gas chromatography-mass spectroscopy. To our knowledge, we are the first group to report the chemical composition of the essential oils derived from the aerial parts of *K. odoratissima*.

## MATERIALS AND METHODS

### Preparation of the plant materials

The aerial parts of *K. odoratissima* were collected from the central Zagros region of western Iran in March 2006. The plant was identified at the Botany Department of Isfahan University, and a voucher specimen (No. 2022) was deposited at the Herbarium of the Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.

**Hydroalcoholic extract:** The air-dried aerial parts of *K. odoratissima* were extracted by maceration at room temperature with ethanol:water (8:2). The extract was concentrated in a rotary evaporator Bibby RE200, UK under reduced pressure to produce a viscous residue. The yield of the extract was 44.4% (w/w). An appropriate amount of the extract was diluted with distilled water (containing 0.5% of Tween 80) to produce the final stock solution.

**Isolation of essential oil:** The air-dried aerial parts of *K. odoratissima* were reduced to a coarse powder, and the oils were isolated by hydrodistillation using a Clevenger-type apparatus for 3 h according to the method recommended in the British Pharmacopoeia.<sup>11</sup> The essential oil was dried over anhydrous sodium sulfate and stored in a sealed vial at 4 °C until analysis. The yield of the oil was calculated based on the dried weight of the plant material. An appropriate amount of essential oil was diluted with distilled water (containing 2 drops of Tween 80 per 10 ml) to produce the final working concentration for pharmacological tests.

### Gas chromatography-mass spectroscopy analysis

Gas chromatography combined with mass spectrometry was used for identification of the components of the essential oil. The analysis was performed on a Hewlett-Packard 6890 gas chromatograph fitted with a fused silica HP-5MS capillary column (30 m × 0.25 mm; coating thickness of 0.25 µm). The oven temperature was programmed to increase from 60 to 280 °C at a rate of 4 °C/min. Helium was used as carrier gas at a flow rate of 2 ml/min. The gas was coupled to a Hewlett-Packard 5972A Mass Selective Detector. The MS operating parameters were the following: ionization voltage of 70 eV and ion source temperature of 200 °C.

### Identification of components

Identification of the components of the essential oil was based on GC retention indices relative to *n*-alkanes and computer matching with the Wiley 275 L mass spectra library. In addition, the analysis included comparisons of

the fragmentation patterns of the mass spectra to those reported in the literature.<sup>12,13</sup>

### Animals

All pharmacological experiments were performed on male NMRI mice (25 to 30 g) that were obtained from the Pasteur Institute (Tehran, Iran). The animals were housed in groups of six in cages at 22 to 25 °C under a 12-h light/dark cycle (lights on at 07:00 h) with free access to food and water. To reduce the influence of diurnal variations, all experiments were conducted from 08:00 to 13:00 h in a special noise-free room with controlled illumination. The experiments were performed in a separate room from where the animals had been habituated. A minimum of six mice were used for each treatment group. The animals were housed and used in accordance with the guidelines of the committee on care and use of laboratory animal resources of the Isfahan University of Medical Sciences.

### Drug preparations

Diazepam hydrochloride was purchased from Chemi Darou (Tehran, Iran) in 10 mg/2 ml ampoules and diluted to an appropriate concentration using normal saline containing 0.5% Tween 80. Different concentrations of the plant extract and essential oil were prepared using normal saline and 0.5% Tween 80. All solutions were prepared fresh on test days and administered i.p. in a volume of 0.1 ml/10 g body weight of mice.

### Elevated plus maze

Anxiolytic activity was measured using the elevated plus maze (EPM) test. The maze consisted of two open (30 cm × 5 cm × 0.2 cm) and two closed (30 cm × 5 cm × 15 cm) arms that extended from a central platform (5 cm × 5 cm) and was elevated to a height of 45 cm above the floor.<sup>14</sup> The entire maze was wooden and painted black.

Mice were administered a single i.p. dose of diazepam, vehicle, extract or essential oil 30 min before their placement on the EPM. At the start of the session, the mouse was placed at the center of the maze facing an open arm, and the number of entries and the time spent in each of the closed and open arms were recorded during a 5-min observation period. Arm entries were defined as the entry of all four paws into the arm. The percentage of open arm entries (100 × open/total entries) and open arm time (100 × open/open+closed arm time) was calculated for each animal. Between each trial, the maze was wiped clean with a damp sponge and dried with paper towels.

### Locomotor activity

To monitor spontaneous locomotor activity, the distance traversed by a mouse in its home cage (measuring 40 × 40 × 20 cm) was monitored via a computerized infrared tracking device (School of Pharmacy, Isfahan). The units for the activity counts were based on the number of beam breaks triggered by the movement of the mouse. Each mouse was injected with a single dose of diazepam, vehicle, extract or essential oil 30 min prior to the test and then placed in a novel cage in the infrared apparatus. The locomotor activity was measured at 5-min intervals for a total of 15 min. Six mice were used for each treatment group. The treatments were randomized throughout the day (between 08:00 and 13:00 h) to control for diurnal variations in activity.

## Statistics

All data are expressed as mean  $\pm$  SEM. The differences among multiple groups were first analyzed by ANOVA. When a statistically significant difference was detected, Dunnett's t-test was used to determine statistical significance among multiple test groups and the corresponding control. A Student's t test was used to evaluate the statistical significance between two groups. These statistical comparisons were analyzed using SigmaStat software (San Jose, CA). Statistical significance was established at 95%.

## RESULTS

### GC-MS analysis

The aerial parts of *K. odoratissima* yielded a 0.4% yellowish essential oil. The identified components and their percentages are given in Table 1, and the components are listed in order of their elution from the HP-5MS column.

### Elevated plus maze

In the elevated plus-maze, 1.5 mg/kg diazepam significantly increased the percentage of time spent and number of entries into the open arms ( $p < 0.05$ ; Figs. 1 A and B). Based on pilot studies, three doses (50, 100 and 200 mg/kg) of the hydroalcoholic extract (HE) and essential oil were evaluated for anxiolytic activities. As shown in Figs. 1 A and B, none of the administered doses of HE or essential oil from *K. odoratissima* significantly changed the percentage of time spent or number of entries into the open arms.

**Table 1** - Percentage composition of the essential oil from *K. odoratissima* leaf analyzed by GC-MS.

No.	Compound	%	RI
1	n-propyl benzene	0.2	953
2	Limonene	t	1028
3	<i>A</i> -terpinolene	0.1	1085
4	Unknown	1.7	1157
5	Unknown	6.2	1282
6	2-undecanone	0.1	1291
7	4-vinyl-2-methoxy phenol	0.2	1312
8	<i>A</i> -cubebene	0.1	1347
9	neryl acetate	t	1363
10	<i>A</i> -copaene	1.4	1372
11	<i>B</i> -cubebene	t	1386
12	<i>B</i> -elemene	t	1387
13	<i>B</i> -caryophyllene	0.3	1414
14	<i>A</i> -humulene	0.2	1450
15	trans- $\beta$ -farnesene	0.1	1453
16	<i>B</i> -acordiene	0.1	1461
17	germacrene-D	0.3	1475
18	$\beta$ -himachalene	0.3	1494
19	Cuparene	0.1	1498
20	germacrene-A	0.2	1503
21	$\beta$ -curcumene	0.3	1511
22	$\delta$ -cadinene	0.7	1522
23	cadina 1,4-diene	0.1	1525
24	cis-3-butylidene phthalide	0.4	1667
25	3-butylidene-4,5-dihydrophthalide	85.9	1735
27	3N butyl phthalide	0.3	1815

ligustilide: 3-butylidene-4,5-dihydrophthalide.  
Retention indices on a HP-5MS capillary column.  
t: trace ( $\leq 0.05\%$ ).  
%: Calculated from TIC data.

### Spontaneous locomotor activity test


The spontaneous locomotor activity was measured at 5-min intervals for 15 min. As shown in Figs. 2 A and B, locomotor activity was significantly decreased in animals injected with diazepam at all three intervals (5, 10 and 15 min), and there was a decrease in the cumulative locomotor activity over the total 15-min test time ( $p < 0.05$ ; Figs. 2 A, B). The effects of HE and the essential oil fraction from *K. odoratissima* on locomotor activity were tested at 50 mg/kg. The HE at 50 mg/kg significantly decreased both locomotor activity in the first and second intervals (5 and 10 min) and the cumulative locomotor activity ( $p < 0.05$ ; Figs. 2 A, B). Although the essential oil fraction decreased the locomotor activity in all three intervals, this decrease was not statistically significant. However, there was a significant decrease in the cumulative locomotor activity after administration of the essential oil of the plant ( $p < 0.05$ ; Figs. 2 A, B).

## DISCUSSION

The aims of the present study were (1) to evaluate the sedative and anxiolytic effects of the HE and essential oils from *K. odoratissima* and (2) to determine the main constituents of the essential oil fraction. To assess the anxiolytic effects of this Iranian plant, an EPM was used to assess anxiety. In agreement with previously published reports, diazepam increased the percentage of time spent and number of entries into the open arms,<sup>15-17</sup> which confirmed the validity of the EPM model and the anxiolytic activity of diazepam.<sup>18</sup> In contrast to diazepam, the total HE and essential oils from *K. odoratissima* did not produce significant increases in the EPM parameters, thereby indicating a lack of anxiolytic-like effects. Several explanations can be given for this lack of an anxiolytic effect. First, it is possible that the plant does not contain any bioactive, detectable constituent to produce anxiolytic effects. Therefore, the calming effect of the plant reported after consuming the dried aerial parts could be due to reduced locomotor activity, which we witnessed in this study.

The other possible reason for not observing the anxiolytic effects of this plant was the experimental model of anxiety. EPM is currently one of the most widely used models of animal anxiety and has been validated in both rats and mice.<sup>19</sup> This test is based on the natural conflict between the drive to explore a new environment and the tendency to avoid a potentially dangerous area. Thus, all behaviors measured in the EPM depend, directly or indirectly, on motor activity, which is probably the main confounding factor in these so-called ethological tests. The approach-avoidance conflict can be resolved by anxiolytic drugs such as benzodiazepines, which produce an increase in the approach levels without necessarily affecting locomotion in the protected areas.<sup>20,21</sup> The EPM model of anxiety has several practical limitations that could also make data interpretation difficult; however, these problems could perhaps be resolved by the addition of a conditional anxiety model.<sup>20,22-25</sup>

Both the total HE and the essential oil fraction from *K. odoratissima* significantly decreased the spontaneous locomotor activity of mice. This reduction in locomotor activity could either be due to the plant's action on the CNS or a direct effect on the periphery. In any case, this effect of *K. odoratissima* is consistent with its folk use as a tranquilizing agent. Further studies are required to determine the mechanism for the sedative action of this plant. *K. odoratissima* has been shown to possess several medicinal properties, which include its activities




**Figure 1** - The effects of diazepam, vehicle and different doses of *K. odoratissima* essential oil and extract on (A) the percentage of time mice spent in the open arms and on (B) the percentage of entries into the open arms during a 5-min test. Various doses of the plant's essential oil or extract, diazepam or vehicle were injected 30 min prior to testing. Data are presented as mean values  $\pm$  SEM for each group of 6 mice. \* $p < 0.05$  compared to control group.

as an anticonvulsant, fibrinolytic, anti-inflammatory agent; it also prevents fatty streak formation. However, no one so far has examined the CNS calming effects of the plant.<sup>26</sup>

The essential oil of *K. odoratissima* consists of 27 components, which represent 99.3% of the total essential oils. The main constituents of the essential oil are phthalides, which include 3-butylidene-4,5-dihydrophthalide (*z*-Ligustilide) (85.9%), *cis*-3butylidene phthalide (0.4%) and 3*N* butyl phthalide (0.3%). The other main identified components of the essential oil of *K. odoratissima* are  $\alpha$ -copaene (1.4%) and  $\delta$ -cadinene (0.7%).

Phthalides, and their corresponding dihydro and tetrahydro analogs, are components of several genera from the plant family Apiaceae.<sup>27</sup> They are bioactive phytochemicals and have important molecular and cellular effects, which include the inhibition of DNMTs (DNA methyltransferases) by targeting DNA hypermethylation,<sup>28</sup> stimulation of glutathione transferase activity,<sup>29</sup> antiproliferative effects on colon cancer cells,<sup>30</sup> potential anti-fibrotic effects for the treatment and prevention of hepatic fibrosis<sup>31</sup> and protective effects on focal cerebral ischemia in rats.<sup>32</sup> Numerous studies have examined the effects of the phthalide family



**Figure 2** - The effects of diazepam, vehicle, and different doses of *K. odoratissima* essential oil and extract on (A) spontaneous locomotor activity during three 5-min intervals and on (B) spontaneous locomotor activity during the total 15 min of testing. The locomotor activity counts (mean ± SEM) were measured over a 15-min period beginning 30 min after the administration of vehicle, diazepam, plant essential oil or extract. Data are presented as mean ± SEM for each group of 6 mice. \* $p < 0.05$  compared to control group.

member, z-Ligustilide (3-butylidene-4,5-dihydrophthalide, LIG). This compound has diverse biological activities, which include smooth muscle relaxation, improved microcirculation, antiasthmatic and analgesic effects, antiproliferative effects on smooth muscle cells and significant neuroprotective effects against transient forebrain ischemia in mice and

focal cerebral ischemia in rats through antioxidant and antiapoptotic mechanisms.<sup>33</sup>

In conclusion, the results of the present study provide evidence for the sedative property of *K. odoratissima*, which may be mediated by the bioactive phthalides<sup>34</sup> contained in this plant. Further studies are underway to examine the

other constituents of this plant and their therapeutic potential.

## ACKNOWLEDGEMENTS

This research received no specific grants from any funding agency in the public, commercial or not-for-profit sectors.

## REFERENCES

1. Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. *Can J Psychiatry*. 2006;51:100-13.
2. Tonks A. Treating generalised anxiety disorder. *BMJ*. 2003;326:700-2, doi: 10.1136/bmj.326.7391.700.
3. Zhang ZJ. Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. *Life Sci*. 2004;75:1659-99, doi: 10.1016/j.lfs.2004.04.014.
4. Hajhashemi V, Rabbani M, Ghanadi A, Davari E. Evaluation of anti-anxiety and sedative effects of essential oil of *Ducrosia anethifolia* in mice. *Clinics*. 2010;65:1037-42, doi: 10.1590/S1807-59322010001000020.
5. von Wilmsdorff M, Bouvier ML, Henning U, Schmitt A, Gaebel W. The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats. *Clinics*. 2010;65:885-94, doi: 10.1590/S1807-59322010000900012.
6. Adam SK, Das S, Othman F, Jaarin K. Fresh soy oil protects against vascular changes in an estrogen-deficient rat model: an electron microscopy study. *Clinics*. 2009;64:1113-9, doi: 10.1590/S1807-59322009001100012.
7. Budin SB, Othman F, Louis SR, Bakar MA, Das S, Mohamed J. The effects of palm oil tocotrienol-rich fraction supplementation on biochemical parameters, oxidative stress and the vascular wall of streptozotocin-induced diabetic rats. *Clinics*. 2009;64:235-44, doi: 10.1590/S1807-59322009000300015.
8. Evans WC. *Trease and Evans' Pharmacognosy*. London: W.B. Saunders Company Ltd.; 2002.
9. Mozaffarian V. Two New Genera of Iranian Umbelliferae. *Bot. Zhurn*. 2003;88:88-94.
10. Ahmadi F, Kadivar M, Shahedi M. Antioxidant activity of *Kelussia odoratissima* Mozaff. in model and food systems. *Food Chem*. 2007;105:57-64.
11. *British Pharmacopoeia*. London: HMSO; 1998.
12. Swigar AA, Silverstein RM. *Monoterpenes. Infrared, Mass, H-NMR, C-NMR Spectra and Kovats Indices*. Wisconsin, USA: Aldrich Chemical Company Inc., 1981.
13. Adams RP. *Identification of Essential Oil Components by Gas Chromatography/Quadrupole Mass Spectroscopy*. Illinois, USA: Allured Publ. Corp., 2004.
14. Emamghoreishi M, Khasaki M, Fath Azam M. *Coriandrum sativum*: evaluation of its anxiolytic effect in the elevated plus-maze. *J Ethnopharmacol*. 2005;96:365-70, doi: 10.1016/j.jep.2004.06.022.
15. Eguchi J, Inomata Y, Saito K. The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism. *Pharmacol Biochem Behav*. 2001;68:677-83, doi: 10.1016/S0091-3057(01)00485-3.
16. Helton DR, Berger JE, Czachura JF, Rasmussen K, Kallman MJ. Central nervous system characterization of the new cholecystokininB antagonist LY288513. *Pharmacol Biochem Behav*. 1996;53:493-502, doi: 10.1016/0091-3057(95)02122-1.
17. Moser PC. An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. *Psychopharmacology (Berl)*. 1989;99:48-53, doi: 10.1007/BF00634451.
18. Soderpalm B, Hjorth S, Engel JA. Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery's conflict test. *Pharmacol Biochem Behav*. 1989;32:259-65, doi: 10.1016/0091-3057(89)90242-6.
19. Treit D. Animal models for the study of anti-anxiety agents: a review. *Neurosci Biobehav Rev*. 1985;9:203-22, doi: 10.1016/0149-7634(85)90046-6.
20. Carobrez AP, Bertoglio LJ. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. *Neurosci Biobehav Rev*. 2005;29:1193-205, doi: 10.1016/j.neubiorev.2005.04.017.
21. Pellow S, Chopin P, File SE, Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. *J Neurosci Meth*. 1985;14:149-67, doi: 10.1016/0165-0270(85)90031-7.
22. Chaouloff F, Durand M, Mormed P. Anxiety and anxiety-related effects of diazepam and chlordiazepoxide in the rat light/dark and dark/light test. *Behav Brain Res*. 1997;85:27-35, doi: 10.1016/S0166-4328(96)00160-X.
23. Costall B, Jones BJ, Kelly ME, Naylor RJ, Tomkins DM. Exploration of mice in a black and white test box: validation as a model of anxiety. *Pharmacol Biochem Behav*. 1989;32:777-85, doi: 10.1016/0091-3057(89)90033-6.
24. Crawley JN. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. *Pharmacol Biochem Behav*. 1981;15:695-9, doi: 10.1016/0091-3057(81)90007-1.
25. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs as an anxiety-like behaviors: a review. *Eur J Pharmacol*. 2003;463:3-33.
26. Asgary S, Naderi G, Dashti G, Paknahad Z. Effect of *Amirkabiria odoratissima mozaffarian* on the development and progression of fatty streaks in hypercholesterolemic rabbits. *Phytother Res*. 2004;18:370-2, doi: 10.1002/ptr.1423.
27. Beck JJ, Chou SC. The structural diversity of phthalides from the Apiaceae. *J Nat Prod*. 2007;70:891-900, doi: 10.1021/np0605586.
28. Yu N, Wang M. Anticancer drug discovery targeting DNA hypermethylation. *Curr Med Chem*. 2008;15:1350-75, doi: 10.2174/092986708784567653.
29. Craig WJ. Health-promoting properties of common herbs. *Am J Clin Nutr*. 1999;70:491S-499S.
30. Kan WL, Cho CH, Rudd JA, Lin G. Study of the anti-proliferative effects and synergy of phthalides from *Angelica sinensis* on colon cancer cells. *J Ethnopharmacol*. 2008;120:36-43, doi: 10.1016/j.jep.2008.07.027.
31. Lee TF, Lin YL, Huang YT. Studies on antiproliferative effects of phthalides from *Ligusticum chuanxiong* in hepatic stellate cells. *Planta Med*. 2007;73:527-34, doi: 10.1055/s-2007-981520.
32. Tian JW, Fu FH, Jiang WL, Wang CY, Sun F, Zhang TP. [Protective effect of *ligusticum chuanxiong* phthalides on focal cerebral ischemia in rats and its related mechanism of action. *Zhongguo Zhong Yao Za Zhi*. 2005;30:466-8.
33. Kuang X, Du JR, Liu YX, Zhang GY, Peng HY. Postischemic administration of *z-Ligustilide* ameliorates cognitive dysfunction and brain damage induced by permanent forebrain ischemia in rats. *Pharmacol Biochem Behav*. 2008;88:213-21, doi: 10.1016/j.pbb.2007.08.006.
34. Kaufman PB, Cseke LJ, Warber S, Duke JA, Briellmann HL. *Natural Products From Plants*. New York: CRC Press, 1999.